Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults

Inclusion Criteria

• Healthy males and females aged 50 to 75 years, inclusive
• Body mass index 18.0 to 35.0 kg/m2, inclusive, and >50 kg body weight
• No clinically significant values for vital signs (systolic blood pressure [BP] 90 to 140 mmHg, diastolic BP 40 to 90 mmHg, and HR 50 to 100 bpm) and no clinically significant ECG readings, as determined by the principal investigator or sub investigator

Exclusion Criteria

• Participation in a clinical research study within the previous 30 days or within a period of less than 5 times the drug's half-life
• Have previously participated in a trial with ALZ-801 or tramiprosate and received study drug
• History of any drug or alcohol abuse in the past 2 years
• Creatinine clearance of \<60 mL/min using the Cockcroft-Gault equation at screening
• Clinically significant abnormal biochemistry, hematology or urinalysis as judged by the investigator
• History of clinically significant cardiovascular, pulmonary, chronic respiratory, renal, hepatic, GI, immunologic, endocrine, neurologic, psychiatric or thromboembolic disease; a history of metabolic disturbances; or any current physical conditions that could interfere with the interpretation of the study results as judged by the investigator